Neuroprotective effect of estrogen after chronic spinal cord injury in ovariectomized rats

BACKGROUND: At present, there is still lack of effective drugs for chronic spinal cord injury, whereas it is found recently that estrogen has a neuroprotective effect on brain and spinal cord injuries. OBJECTIVE: To observe the effect of estrogen on the apoptosis of nerve cells after gradual chronic spinal cord injury in ovariectomized rats. DESIGN: A randomized controlled animal trial. SETTING: Institute of Orthopaedics, the Second Hospital of Lanzhou University. MATERIALS: Sixty-five female Wistar rats of common degree, weighing 220–250 g, were provided by the experimental animal center of Lanzhou University. The rats were randomly divided into sham-operated group (n =5), estrogen-treated group (n =30) and saline control group (n =30), and the latter two groups were observed at 1, 3, 7, 14, 28 and 60 days respectively, and 5 rats for each time point. METHODS: All the rats were treated with bilateral oophorectomy 2 weeks before the experiment. T10 vertebral lamina was revolved into using plastic screw. The spinal canal impingement was not induced initially. After that, the original incision was opened to expose the screw every 7–10 days. MAIN OUTCOME MEASURES: The apoptosis and Caspase-3 positive cells in the damaged spinal cord were detected using terminal deoxynucleotidal transferase-mediated dUTP-biotin nick end labeling (TUNEL) method and Caspase-3 immunohistochemical staining at 1, 3, 7, 14, 28 and 60 days after chronic spinal cord injury respectively. RESULTS: Totally 65 rats were used, and the deleted ones during the experiment were supplemented by others. Changes of Caspase-3 expression after spinal cord injury: In the sham-operated group, only a small amount of Caspase-3 proteins were observed in the rat spinal cord, mainly located in motor neurons of spinal cord anterior horn. In the estrogen-treated group and saline control group, positive cells expressed occasionally at 1 day postoperatively, began to increase obviously at 7 days after injury, strongly expressed at 14 and 28 days, but decreased at 60 days, mainly located in the neurons of spinal cord gray matter anterior horn, and they expressed fewer in the motor neurons and white matter of ventral horn, and there were obvious differences between the estrogen-treated group and saline control group at 7, 14, 28 and 60 days (P < 0.05). CONCLUSION: Estrogen can reduce the apoptosis of nerve cells and promote the recovery of neurological function following gradual chronic spinal cord injury.     

原发性骨膜增生厚皮症伴重度贫血1例

患者男,39岁,面部皮肤肥厚、四肢肢端肥大20年,间断头晕乏力1年.查体:重度贫血貌,睑结膜、口唇及甲床苍白;头面部皮肤肥厚、皱褶、呈回状颅皮;双下肢皮肤肥厚,手指及足趾呈杵状;皮损颜色正常,触之略韧;踝关节肿胀无压痛、活动自如.X线检查提示右腓骨中段髓腔密度增多,腓骨中段及胫骨下段后缘骨皮质增厚.血常规重度正常细胞低...     

Diagnostic significance of long non-coding RNAs expression in tuberculosis patients: A systematic review and meta-analysis

Objectives:It is crucial to identify effective diagnostic biosignatures of tuberculosis (TB) to optimize its treatment. Herein, we conducted a systematic review to elucidate the diagnostic efficacy of long noncoding RNA (lncRNAs) as TB biomarkers.Methods:We searched Medline, Web of Science, Embase, Cochrane Library, CNKI, Wanfang, VIP, and China Biology Medicine disc databases up to February 18, 2020. These studies focusing on lncRNAs as diagnosis markers of TB were collected. STATA 12.0 and Meta-disc1.4 software were used to analyze the data extracted from eligible studies.Results:We included 8 articles with 1058 TB patients, and 1896 healthy controls in our study. The values of pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.63, 0.86, 4.48, 0.43, and 10.31, respectively. Additionally, we plotted the summary receiver operating characteristic curve to evaluate the diagnostic accuracy, and the area under the curve was 0.80.Conclusion:The present study is the first meta-analysis to assess the diagnostic accuracy of lncRNAs in TB patients. We found that lncRNAs might constitute potential biomarkers for the diagnosis of TB patients. More population-based high-quality research should be conducted to validate the efficacy lncRNAs in TB patients.     

α-生育酚琥珀酸酯和三氧化二砷对阿霉素诱导的白血病细胞耐药性的预防作用

目的 观察α-生育酚琥珀酸酯（α-TOS）和As2O3对阿霉索（ADM）诱发的白血病细胞耐药的预防作用。方法 以白血病K562细胞为模型,模拟临床化疔过程。采用间歇性给药、逐渐增量的方法诱导K562细胞对ADM产生耐药性;同时并用α-TOS或As2O3,以观察其对ADM诱导耐药性产生的影响。MTT法检测细胞耐药性,免疫荧光法观察P-糖蛋白（P-gp）表达。荧光显微镜观察细胞内ADM含量。结果 经ADM诱导5个月后,K562细胞对ADM的耐受性增高约4倍．并与柔红霉素交叉耐药,P-gP表达增加,细胞内ADM的蓄积量降低;同时并用α-TOS或As2O3可不同程度地降低ADM诱导的K562细胞P-gP的表达水平和增加细胞内ADM含量,减低或延缓耐药性发生。结论 α-TOS和As2O3可降低或延缓ADM诱导的白血病细胞耐药性的发生,其机制可能为抑制P-gp的表达。     

肾上腺素联合艾司洛尔对心室颤动复苏模型家兔肺水肿的影响

目的:探讨肾上腺素联合艾司洛尔对心室颤动复苏家兔复苏早期肺水肿及心脏标志物的影响。方法:将26只清洁级家兔随机分为3组,其中20只清洁级家兔采用交流电致心室颤动建立心肺复苏模型,另6只为手术对照组(A组),仅行麻醉、手术、气管插管,不制作心肺复苏模型。模型家兔随机均分10只,分别在复苏时给予肾上腺素10μg/kg(B组)和在复苏时给予肾上腺素10μg/kg+艾司洛尔200μg/kg(C组)。测量复苏成功后5 h肺湿/干比重,比较复苏后30 min、1 h、2 h、4 h时血清肌钙蛋白(cTnI)水平及丙二醛(MDA)活性的变化。结果:A、C、B组家兔于模型复苏成功后5 h肺湿/干比重、cTnI水平和MDA活性依次升高,差异均有统计学意义(P0.01～P0.05)。结论:艾司洛尔可以减轻家兔心室颤动复苏后肺水肿,对复苏后早期心脏有保护作用。     

磁敏感加权成像对脑梗死临床应用的研究进展

脑梗死是目前严重危害老年人健康的疾病之一,早期诊断、及时有效的治疗对其预后有着重要的意义。磁敏感加权成像(SWI)可以清晰地显示脑静脉血管及病灶内的出血灶,特别是对微出血的检出具有明显的优势,能为脑梗死的诊断提出更多有价值的信息。现对SWI在反映脑梗死演变过程、显示脑血凝块、检测脑梗死后出血及评价梗死周围组织活性方面的临床应用进行文献回顾,同时提出SWI技术在脑梗死应用中的优势与不足。     

胶原三维立体培养模型中胚肺成纤维细胞与肺癌GLC-82细胞的相互作用

背景：组织细胞、炎细胞可能在肿瘤细胞的侵袭、转移中发挥着重要作用,而细胞间的相互作用对基质金属蛋白酶有影响。 目的：观察胚肺成纤维细胞与肺癌GLC-82细胞在胶原三维立体培养条件下,相互作用对基质金属蛋白酶1,2,9表达的影响。 方法：采用三维胶原立体培养模型,按比例混合胶原,4倍DMEM和灭菌水,1倍DMEM的液体胶原,其中胶原终浓度为0.75 g/mL。将GLC-82细胞、胚肺成纤维细胞分别单独培养及GLC-82细胞和胚肺成纤维细胞按5∶1混合培养,待胶原固化后加入1倍DMEM培养基,48 h后收集上清液。Western blot法检测基质金属蛋白酶1表达水平,明胶酶谱法测定基质金属蛋白酶2,9的表达。 结果与结论：胚肺成纤维细胞与肺癌GLC-82细胞混合培养组基质金属蛋白酶1及基质金属蛋白酶2,9分泌量大于单独培养组(P < 0.05)。结果提示,三维立体培养条件下,胚肺成纤维细胞与肺癌GLC-82细胞相互作用能通过上调基质金属蛋白酶1,2,9的表达和活化,促进肺癌侵袭和转移。     

替吉奥联合奥沙利铂对比替吉奥联合顺铂治疗晚期胃癌的Meta分析

目的评价替吉奥联合奥沙利铂（SOX方案）对比替吉奥联合顺铂（SP方案）治疗晚期胃癌（AGC）的疗效及安全性。 方法在PubMed、Embase、Web of Science、中国期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、万方数据库、维普中文科技期刊数据库中检索2022年7月前公开发表的有关替吉奥联合奥沙利铂（SOX组）对比替吉奥联合顺铂（SP组）治疗AGC的相关研究,按照Cochrane Handbook 5.1的临床试验质量评价标准对文献进行质量评价,采用RevMan 5.4软件进行Meta分析。 结果共有14篇2 650例AGC患者纳入研究,其中SOX组1 334例,SP组1 316例。与SP组比较,SOX组的总生存期（HR=0.87,95% CI：0.78~0.97,P=0.01）、无进展生存期（HR=0.87,95% CI：0.78~0.97,P=0.01）、完全缓解（OR=1.43,95% CI：1.02~2.00,P=0.04）、部分缓解（OR=1.64,95% CI：1.18~2.29,P=0.003）、疾病进展（OR=0.55,95% CI：0.34~0.87,P=0.01）、疾病控制率（OR=1.64,95% CI：1.04~2.56,P=0.03）和疾病稳定（OR=0.67,95% CI：0.53~0.83,P=0.000 4）方面比较,差异均有统计学意义,而两组客观有效率差异无统计学意义（OR=1.57,95% CI：0.85~2.90,P=0.15）。安全性方面,3级及以上不良反应中,SOX组白细胞减少（OR=0.20,95% CI：0.13~0.30,P<0.000 01）、贫血（OR=0.52,95% CI：0.32~0.86,P=0.01）、肌酐升高（OR=0.21,95% CI：0.07~0.61,P=0.004）的发生率更低,而周围感觉神经病（OR=10.64,95% CI：1.85~61.10,P=0.008）的发生率更高。 结论SOX方案可提高AGC的治疗有效率,改善无进展生存期和总生存期,但可能增加周围感觉神经病的发生率。